Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids

Objectives: To characterise and quantify the CD4+ CD25+ T cell population in patients with systemic lupus erythematosus (SLE) and to detect the possible influence of treatments and clinical manifestations. Methods: Characterisation of CD25low and CD25high CD4+ T cells from healthy controls and from patients with SLE was carried out using flow cytometry, analysing the expression of activation and differentiation markers. The percentage of both circulating cell subsets was determined in 56 controls and 110 unselected patients with SLE. Data were related to treatment during the past 3 months and to various clinical manifestations. Results: CD4+ CD25high lymphocytes from controls expressed low levels of CD69, CD154 or CD30, but also expressed glucocorticoid-induced tumour necrosis factor receptor, high levels of intracellular cytotoxin T lymphocyte-associated antigen 4, CD45RO and diminished amounts of CD4, all of which are phenotypic characteristics of natural regulatory T cells. CD4+ CD25low cells, on the other hand, expressed the highest levels of activation markers, indicating that they represent recently activated effector cells. Similarly, analysis of cells from patients with SLE showed the same two phenotypically distinguishable CD4+ CD25low and CD4+ CD25high populations, although both expressed slightly increased levels of activation markers. Quantitative analysis showed a considerably raised percentage of CD25low and, especially, CD25high cells in patients with SLE compared with controls. This increment was unrelated to clinical manifestations, but correlated with glucocorticoid treatment. Patients treated with glucocorticoids presented raised levels of CD25high cells, whereas untreated patients and those with anti-malarial or immunosuppressive drugs had levels similar to those in controls. Conclusions: The percentage of CD4+ CD25high cells was not altered in non-steroid-treated patients, whereas glucocorticoid treatment increased their frequency in patients with SLE.

[1]  X. Mariette,et al.  CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome. , 2005, Journal of autoimmunity.

[2]  S. Sánchez-Ramón,et al.  Pregnancy-induced expansion of regulatory T-lymphocytes may mediate protection to multiple sclerosis activity. , 2005, Immunology letters.

[3]  C. Akdis,et al.  Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. , 2004, The Journal of allergy and clinical immunology.

[4]  N. Hassanein,et al.  Effects of IL-7 and dexamethasone: induction of CD25, the high affinity IL-2 receptor, on human CD4+ cells. , 2004, Cellular immunology.

[5]  L. Harrison,et al.  TCR-mediated activation promotes GITR upregulation in T cells and resistance to glucocorticoid-induced death. , 2004, International immunology.

[6]  J. Bijlsma,et al.  CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. , 2004, Arthritis and rheumatism.

[7]  S. Ziegler,et al.  Cutting Edge: Estrogen Drives Expansion of the CD4+CD25+ Regulatory T Cell Compartment1 , 2004, The Journal of Immunology.

[8]  D. Vergani,et al.  Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. , 2004, Journal of hepatology.

[9]  L. Klareskog,et al.  CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease , 2004, Arthritis research & therapy.

[10]  H. Lorenz,et al.  Defective Suppressor Function of Human CD4+ CD25+ Regulatory T Cells in Autoimmune Polyglandular Syndrome Type II , 2004, The Journal of experimental medicine.

[11]  M. Drayson,et al.  Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T‐cell subset , 2004, Immunology.

[12]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[13]  R. Pirskanen,et al.  Circulating CD4+CD25+ and CD4+CD25– T Cells in Myasthenia Gravis and in Relation to Thymectomy , 2004, Scandinavian journal of immunology.

[14]  Xin Chen,et al.  Differential response of murine CD4+CD25+ and CD4+CD25– T cells to dexamethasone‐induced cell death , 2004, European journal of immunology.

[15]  H. Link,et al.  Circulating CD4+CD25+ T Regulatory Cells Are Not Altered in Multiple Sclerosis and Unaffected by Disease-Modulating Drugs , 2004, Journal of Clinical Immunology.

[16]  L-L Fung,et al.  Decreased CD4+CD25+ T Cells in Peripheral Blood of Patients with Systemic Lupus Erythematosus , 2004, Scandinavian journal of immunology.

[17]  C. Gutiérrez,et al.  Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features , 2003, Lupus.

[18]  J. Alcocer-Varela,et al.  Quantification of regulatory T cells in patients with systemic lupus erythematosus. , 2003, Journal of autoimmunity.

[19]  C. Baecher-Allan,et al.  Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis , 2003, European journal of immunology.

[20]  R. Lechler,et al.  Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. , 2001, Blood.

[21]  G. Freeman,et al.  CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.

[22]  G. Schuler,et al.  Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.

[23]  A. Enk,et al.  Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood , 2001, The Journal of experimental medicine.

[24]  W. Waldhäusl,et al.  Increased CD69 and human leukocyte antigen-DR expression on T lymphocytes in insulin-dependent diabetes mellitus of long standing. , 1998, The Journal of clinical endocrinology and metabolism.

[25]  C. Chuang,et al.  CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity , 1997, Lupus.

[26]  M. Feldmann,et al.  The majority of the activated T cells in the blood of insulin-dependent diabetes mellitus (IDDM) patients are CD4+. , 1988, Clinical and experimental immunology.

[27]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[28]  M. Peakman,et al.  Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. , 2005, Diabetes.

[29]  Svetlana Ten,et al.  Multiple immuno-regulatory defects in type-1 diabetes. , 2002, The Journal of clinical investigation.